Electrome is currently closing its $3.0M funding round. Success in fully subscribing this round will heavily indicate that institutional investors have reviewed Electrome’s regulatory data room and validated their reimbursement thesis.
Summary of the Strategy's Success and OutlookElectrome's reimbursement strategy is highly strategic but its success depends entirely on where and how the specific product is used. The NOPAIN Act is strictly limited to treatments administered inside outpatient surgical centers and hospital outpatient departments; it does not cover at-home chronic pain management.
Because of these tight regulatory boundaries, Electrome’s two core device lines face completely different outlooks:
High Success Probability (RecoveryRx): This product is used by clinicians for post-operative recovery and wound care directly in outpatient surgical settings. Because it fits the strict legal definition of the NOPAIN Act, Electrome has a clear, highly viable pathway to secure dedicated Medicare reimbursement codes for it.
Low Success Probability via This Pathway (ActiPatch): This device is designed for at-home, direct-to-consumer management of chronic musculoskeletal pain. Because the NOPAIN Act explicitly excludes take-home consumer technology for general chronic pain, Electrome will not be able to use this pathway for ActiPatch. Instead, these sales will have to rely on traditional commercial insurance or direct cash payments.
Summary of the Strategy's Success and OutlookElectrome's reimbursement strategy is highly strategic but its success depends entirely on where and how the specific product is used. The NOPAIN Act is strictly limited to treatments administered inside outpatient surgical centers and hospital outpatient departments; it does not cover at-home chronic pain management.
Because of these tight regulatory boundaries, Electrome’s two core device lines face completely different outlooks:
High Success Probability (RecoveryRx): This product is used by clinicians for post-operative recovery and wound care directly in outpatient surgical settings. Because it fits the strict legal definition of the NOPAIN Act, Electrome has a clear, highly viable pathway to secure dedicated Medicare reimbursement codes for it.
Low Success Probability via This Pathway (ActiPatch): This device is designed for at-home, direct-to-consumer management of chronic musculoskeletal pain. Because the NOPAIN Act explicitly excludes take-home consumer technology for general chronic pain, Electrome will not be able to use this pathway for ActiPatch. Instead, these sales will have to rely on traditional commercial insurance or direct cash payments.
1
